Big Move in Autoimmune Space: Aurinia to Buy Kezar Life Sciences
Aurinia Pharmaceuticals has agreed to acquire Kezar Life Sciences for $6.955 in cash per share plus a Contingent Value Right (CVR).
/ 3 items
#AUPH↓
Jefferies Upgrades Aurinia Pharmaceuticals to Buy, Raises Target to $21
Jefferies upgrades Aurinia Pharmaceuticals to Buy, boosting the price target to $21 on strong Lupkynis sales and promising pipeline prospects.
FDA Scrutinizes Aurinia's Voclosporin Toxicity and Surrogate Endpoints
A top FDA official flagged the drug voclosporin as highly toxic, noting it was approved too quickly using ‘stand-in’ results (surrogate endpoints) without proving a direct benefit to patients. The FDA will now review this process to ensure approved drugs deliver real clinical results.